Total Payments
$97,650
2024 Payments
$3,997
Companies
14
Transactions
82
Medicare Patients
3,324
Medicare Billing
$1.5M
Payment Breakdown by Category
Consulting$47,873 (49.0%)
Research$30,334 (31.1%)
Other$16,471 (16.9%)
Travel$1,934 (2.0%)
Food & Beverage$1,032 (1.1%)
Education$7.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $47,873 | 22 | 49.0% |
| Unspecified | $30,334 | 14 | 31.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,471 | 18 | 16.9% |
| Travel and Lodging | $1,934 | 10 | 2.0% |
| Food and Beverage | $1,032 | 16 | 1.1% |
| Education | $7.74 | 2 | 0.0% |
Payments by Type
General
$67,316
68 transactions
Research
$30,334
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $26,078 | 29 | $0 (2023) |
| Janssen Research & Development, LLC | $22,364 | 4 | $0 (2022) |
| ABBVIE INC. | $22,289 | 29 | $0 (2024) |
| Genentech USA, Inc. | $5,866 | 5 | $0 (2024) |
| Immunocore Limited | $5,000 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $3,818 | 5 | $0 (2021) |
| Chugai Pharmaceutical Co., Ltd. | $3,300 | 1 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,156 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $2,055 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $1,905 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,997 | 4 | ABBVIE INC. ($3,950) |
| 2023 | $7,512 | 6 | Immunocore Limited ($5,000) |
| 2022 | $4,086 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($3,156) |
| 2021 | $30,047 | 8 | Janssen Research & Development, LLC ($21,434) |
| 2020 | $14,006 | 12 | F. Hoffmann-La Roche AG ($7,175) |
| 2019 | $13,729 | 13 | F. Hoffmann-La Roche AG ($10,427) |
| 2018 | $16,424 | 19 | AbbVie, Inc. ($11,990) |
| 2017 | $7,850 | 17 | AbbVie, Inc. ($5,157) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/12/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,537.50 | General |
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 05/31/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $62.79 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | Gavreto (Drug) | — | In-kind items and services | $1,550.50 | Research |
| Study: BLU667 1101 ARROW ongoing • Category: BioOncology | ||||||
| 08/04/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $760.00 | General |
| Category: ONC | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $65.87 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 06/02/2023 | AbbVie Inc. | — | — | In-kind items and services | $26.47 | Research |
| Study: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | ||||||
| 05/30/2023 | Immunocore Limited | KIMMTRAK (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Oncology | ||||||
| 03/31/2023 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $108.84 | Research |
| Study: The timing, dynamics, and co-occurrence of immune-related adverse events (irAEs) with a PD-L1 inhibitor in non-small cell lung cancer • Category: BioOncology | ||||||
| 11/23/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $930.00 | General |
| 06/14/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 06/09/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $5.59 | General |
| 11/01/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 10/14/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 08/11/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 07/29/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 06/30/2021 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,905.00 | General |
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $772.97 | Research |
| Study: A PHASE IIII, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB ANTIPD-L1 ANTIBODY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 02/19/2021 | Chugai Pharmaceutical Co., Ltd. | TECENTRIQ (Biological) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: BioOncology | ||||||
| 01/21/2021 | Janssen Research & Development, LLC | — | — | Cash or cash equivalent | $20,634.00 | Research |
| Study: Amyloidosis Project | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $921.55 | Research |
| Study: 1L SCLC ED • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $609.48 | Research |
| Study: 1L SCLC ED • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $3,359.55 | Research |
| Study: A PHASE IIII, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB ANTIPD-L1 ANTIBODY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $594.19 | Research |
| Study: A PHASE IIII, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB ANTIPD-L1 ANTIBODY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Amyloidosis Project | Janssen Research & Development, LLC | $20,634 | 1 |
| A PHASE IIII, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB ANTIPD-L1 ANTIBODY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $6,417 | 7 |
| BLU667 1101 ARROW ongoing | F. Hoffmann-La Roche AG | $1,551 | 1 |
| 1L SCLC ED | F. Hoffmann-La Roche AG | $1,531 | 2 |
| The timing, dynamics, and co-occurrence of immune-related adverse events (irAEs) with a PD-L1 inhibitor in non-small cell lung cancer | F. Hoffmann-La Roche AG | $108.84 | 1 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | AbbVie Inc. | $92.34 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 820 | 26,390 | $2.1M | $542,272 |
| 2022 | 24 | 653 | 14,755 | $1.3M | $356,587 |
| 2021 | 28 | 976 | 17,789 | $898,921 | $278,368 |
| 2020 | 29 | 875 | 14,155 | $937,042 | $324,911 |
Total Patients
3,324
Total Services
73,089
Medicare Billing
$1.5M
Procedure Codes
110
All Medicare Procedures & Services
110 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 26 | 7,400 | $1.0M | $291,068 | 28.1% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 3,063 | $430,394 | $113,486 | 26.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 4,000 | $340,735 | $94,660 | 27.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 120 | 145 | $107,010 | $15,349 | 14.3% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 12 | 895 | $7,289 | $4,056 | 55.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 13 | 18 | $13,590 | $3,809 | 28.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 55 | $15,345 | $3,259 | 21.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 44 | 55 | $19,250 | $2,826 | 14.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 28 | 40 | $7,560 | $2,796 | 37.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 76 | 176 | $24,112 | $2,139 | 8.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 36 | 79 | $15,405 | $1,860 | 12.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 20 | $5,800 | $1,825 | 31.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 30 | 51 | $8,568 | $1,162 | 13.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 18 | $2,448 | $720.80 | 29.4% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 12 | 203 | $2,103 | $574.55 | 27.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 21 | 4,350 | $4,603 | $548.02 | 11.9% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 23 | 3,756 | $6,629 | $360.06 | 5.4% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 16 | 22 | $2,442 | $353.32 | 14.5% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 14 | 168 | $4,896 | $320.18 | 6.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 16 | 25 | $1,975 | $284.20 | 14.4% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 21 | 138 | $5,130 | $257.34 | 5.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 14 | 18 | $2,052 | $185.23 | 9.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 16 | 200 | $2,267 | $154.69 | 6.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 54 | 718 | $2,633 | $69.07 | 2.6% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 55 | 672 | $2,924 | $50.45 | 1.7% |
About Dr. Aaron Mansfield, MD
Dr. Aaron Mansfield, MD is a Internal Medicine healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1437278959.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Mansfield, MD has received a total of $97,650 in payments from pharmaceutical and medical device companies, with $3,997 received in 2024. These payments were reported across 82 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($47,873).
As a Medicare-enrolled provider, Mansfield has provided services to 3,324 Medicare beneficiaries, totaling 73,089 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 110 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Rochester, MN
- Active Since 03/28/2007
- Last Updated 08/18/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1437278959
Products in Payments
- TECENTRIQ (Biological) $20,572
- Tecentriq (Biological) $7,284
- KIMMTRAK (Drug) $5,000
- Alecensa (Biological) $4,373
- OPDIVO (Biological) $2,679
- TAGRISSO (Drug) $2,055
- Gavreto (Drug) $1,551
- Non-Covered Product (Drug) $1,320
- Venclexta (Drug) $1,100
- Trodelvy (Drug) $760.00
- Avastin (Biological) $126.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Rochester
Dr. Ben George, M.d, M.D
Internal Medicine — Payments: $729,795
Internal Medicine $729,795
John Kisiel, M.d, M.D
Internal Medicine — Payments: $550,377
Internal Medicine $550,377
Gregory Poland, M.d, M.D
Internal Medicine — Payments: $532,099
Internal Medicine $532,099
Christopher Ritchlin, Md, MD
Internal Medicine — Payments: $512,889
Internal Medicine $512,889
Scott Feitell, D.o, D.O
Internal Medicine — Payments: $471,187
Internal Medicine $471,187
Prashant Kapoor, Md, MD
Internal Medicine — Payments: $403,295
Internal Medicine $403,295